Seeking growth in the stagnant US chewing gum market, 109-year-old major player Wm. Wrigley Jr. Co. is embarking on its first medicinal-gum venture with Surpass. Containing antacids, Surpass is intended to take Wrigley into the profitable pharmaceutical aisle, where other gums containing aspirin or antacids already exist. The market is large enough for the producers to co-exist however, and Wrigley has now formed a health care division with the intention of exploring other possibilities for medicinal gum.